Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Heering

Showing results (11-20 of 86) with videos related to

Pageof 9
Sort By:
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|August 1, 1996
Systemic ciclosporin A in high-risk keratoplastiesT Reinhard, R Sundmacher, P Heering
Journal of Clinical Pathology|April 29, 2004
COX-2 dependent PGE(2) downregulates alpha(v) integrin expression via the EP(3) receptor in cultured mesangial cellsC Waldner, K Schrör, P Heering
Der Internist|June 1, 1997
[Immunosuppression in therapy of glomerulonephritis]B Grabensee, D Bach, P Heering
Deutsche Medizinische Wochenschrift (1946)|May 29, 2003
[Gitelman's syndrome: an important differential diagnosis of hypokalemia]C Kurschat, P Heering, B Grabensee
German Journal of Ophthalmology|January 1, 1992
Six years' experience with systemic cyclosporin A prophylaxis in high-risk perforating keratoplasty patients. A retrospective studyR Sundmacher, T Reinhard, P Heering
Der Internist|December 1, 1990
[Continuing education. Hematuria]P Heering, S Schauseil, B Grabensee
Klinische Monatsblatter Fur Augenheilkunde|December 1, 1990
[Preventive systemic cyclosporin A in risk keratoplasty]V Rossa, R Sundmacher, P Heering
Kidney & Blood Pressure Research|May 29, 2003
Cytokine removal in septic patients with continuous venovenous hemofiltrationP Heering, B Grabensee, M Brause
Medizinische Klinik (Munich, Germany : 1983)|November 11, 1999
[Systemic Al-amyloidosis. Clinical course and limits of melphalan therapy]G R Hetzel, P Heering, B Grabensee
International Urology and Nephrology|April 9, 1999
Cardiovascular risk factors and diseases after renal transplantationS Aker, K Ivens, B Grabensee, et al.
Pageof 9

Showing results (11-20 of 86) with videos related to

Sort By:
Pageof 9
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|August 1, 1996
Systemic ciclosporin A in high-risk keratoplastiesT Reinhard, R Sundmacher, P Heering
Journal of Clinical Pathology|April 29, 2004
COX-2 dependent PGE(2) downregulates alpha(v) integrin expression via the EP(3) receptor in cultured mesangial cellsC Waldner, K Schrör, P Heering
Der Internist|June 1, 1997
[Immunosuppression in therapy of glomerulonephritis]B Grabensee, D Bach, P Heering
Deutsche Medizinische Wochenschrift (1946)|May 29, 2003
[Gitelman's syndrome: an important differential diagnosis of hypokalemia]C Kurschat, P Heering, B Grabensee
German Journal of Ophthalmology|January 1, 1992
Six years' experience with systemic cyclosporin A prophylaxis in high-risk perforating keratoplasty patients. A retrospective studyR Sundmacher, T Reinhard, P Heering
Der Internist|December 1, 1990
[Continuing education. Hematuria]P Heering, S Schauseil, B Grabensee
Klinische Monatsblatter Fur Augenheilkunde|December 1, 1990
[Preventive systemic cyclosporin A in risk keratoplasty]V Rossa, R Sundmacher, P Heering
Kidney & Blood Pressure Research|May 29, 2003
Cytokine removal in septic patients with continuous venovenous hemofiltrationP Heering, B Grabensee, M Brause
Medizinische Klinik (Munich, Germany : 1983)|November 11, 1999
[Systemic Al-amyloidosis. Clinical course and limits of melphalan therapy]G R Hetzel, P Heering, B Grabensee
International Urology and Nephrology|April 9, 1999
Cardiovascular risk factors and diseases after renal transplantationS Aker, K Ivens, B Grabensee, et al.
Pageof 9